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Early relapse of acute myeloid leukemia (AML) after allogeneic hematopoietic stem
cell transplantation (allo-HSCT) is an often unsuccessful therapeutic challenge. Since
treatment options are few and efficacy is low, new approaches such as de novo
allo-HSCT, targeted therapies and biomodulatory drugs have been developed, albeit
prognosis is very poor. In this manuscript we present an unusual case of a patient with
high-risk AML with an unbalanced jumping translocation and FLT3-TKD (low) mutation
who presented with early relapse (FLT3 negative) after allo-HSCT, refractory to one cycle
of azacytidine and discontinuation of immunosuppression (IS). As salvage therapy, the
patient received a biomodulatory therapy consisting of low-dose azacytidine 75 mg/day
(given s.c. d1–7 of 28), pioglitazone 45mg/day orally, and all-trans-retinoic acid (ATRA) 45
mg/m2/day orally achieving a complete remission after two cycles of therapy. Even after
cessation of treatment after 5 cycles, the patient remained in complete remission with
full chimerism in peripheral blood and bone marrow for another 7 months. In conclusion,
we report about an unusual case of long-lasting complete remission of early relapsed
high-risk AML after allo-HSCT treated with azacytidine, pioglitazone and ATRA after
standard of care treatment with HMA and discontinuation of IS failed.
Keywords: acute myeloid leukemia, relapse, allogeneic stem cell transplantation, biomodulatory treatment,
anakoinosis
INTRODUCTION
Relapse of AML, especially after allo-HSCT is difficult to treat as there are few therapeutic options
promising sustained effects. Long-term survival in transplanted patients with AML relapse has
been described as low as 10%. Aspects such as FMS-like tyrosine kinase 3 (FLT3) mutations
or failure to respond to the first induction cycle, as was the case presented here, are adverse
risk factors for relapse and outcome (1). FLT3 is a ligand-activated receptor tyrosine kinase
expressed mainly in hematopoietic stem and progenitor cells (2). FLT3-TKD (tyrosine kinase
domain) mutations, also present in our patient, are mostly point mutations in codons D835 and
I836 leading to constitutive tyrosine phosphorylation with subsequent activation of FLT3 which
Kattner et al. Biomodulatory Therapy of AML-Relapse After allo-HSCT
leads to cell proliferation and is associated with poor prognosis
(3–6). In FLT3-ITD (internal tandem duplication) mutated AML
patients, low mutant-to-wildtype allelic ratio is associated with
better overall survival (OS) compared to patients with high
mutant-to-wildtype allelic ratio (7). However, less is known about
TKD mutations. Their impact on survival does not seem as
significant at this point (8, 9). Relapse within 6 months after
allo-HSCT and high blast count in bone marrow are further risk
factors for worse outcome (10). Established therapy regimens
include hypomethylating agents (HMA) (11), discontinuation of
IS and donor lymphocyte infusion (DLI) (12) as early preemptive
or molecular recurrence treatment options while in cases of
hematologic relapse, chemotherapy (13) and DLI are therapeutic
options (14). In case of FLT3-ITD mutation, tyrosine kinase
inhibitors (TKI) are a promising option leading to longterm
survival in some patients (15). This sustained response was
explained by an increase in IL15 production by AML cells
acting synergistically in combination with allogeneic CD8+ T
cell response in a mouse model of FLT3-ITD mutated AML (16).
However, in case the mutation is lost during relapse, it is unclear
whether these effects of TKI remain and generally speaking,
data is limited at this point. Therefore, other therapeutic options
are needed to further improve prognosis of relapsed patients
after allo-HSCT. At our center, a biomodulatory regimen was
developed showing efficacy in patients with refractory/relapsed
AML (without allo-HSCT) in small case studies (17, 18) as well
as an ongoing prospective randomized clinical trial (AMLSG26-
16/AML-ViVA) (19). The biomodulatory regimen (termed APA)
consists of low-dose azacytidine 75 mg/day (given s.c. d1–7 of
28), pioglitazone 45 mg/day orally, and all-trans-retinoic acid
(ATRA) 45 mg/m2/day orally. In vitro experiments showed
that the biomodulatory combination leads to a differentiation
of AML blasts into neutrophil like cells capable of production
of reactive oxygen species and phagocytosis (20), especially in
relapsed/refractory AML patients with FLT3-ITD mutations.
However, this is the first report on APA treatment of a patient that
relapsed with high-risk AML (within 3 months) after allogeneic
hematopoietic stem cell transplantation.
CASE PRESENTATION
The 55-year old female patient first presented with increased
tendency to bleed and respiratory infection. Past medical
history consisted of pulmonary emphysema associated with
smoking (40 pack years), allergy to ciprofloxacin and osteopenia.
Peripheral blood count on admittance to our hospital showed
pancytopenia with absolute neutropenia (0/nl) and myeloid
blasts. Cytomorphology and flow cytometry confirmed bone
marrow infiltration by AML (FAB M1) blasts in 42% of
nucleated cells. Cytogenetic analysis revealed an unbalanced
jumping translocation, a cytogenetic aberration where one
chromosome segment has fused with two or more other
chromosomes, associated with poor response to HMA and
chemotherapy as well as poor survival (21). Molecular genetic
testing diagnosed a FLT3-TKD low (low mutant-to-wildtype
allelic ratio <0.5) mutation. The first induction cycle (cytarabine
and daunorubicine 7 + 3 day schedule) failed to induce
remission. Therefore, the 2nd induction cycle was changed to
a high-dose cytarabine and mitoxantrone (HAM) regimen in
combination with midostaurin (a FLT3 inhibitor) which has
been shown to improve OS and event free survival (EFS) in
FLT3-mutated AML patients in combination with chemotherapy
(22). The following bone marrow aspirate detected minimal
residual disease (MRD) with incomplete regeneration creating
an adverse risk situation. The patient therefore proceeded to
receive an allo-HSCT from a DQB1-mismatched unrelated
donor with fludarabine, thiotepa, and busulfan as conditioning
regimen. On day 30 post-transplant, complete remission was
confirmed by bone marrow aspirate (with 100% chimerism).
Signs of mild acute skin and gastrointestinal GvHD (which
began day 53 post-transplant) were treated topically and with
prednisolone (2.4 mg/kg/d) systemically. Signs of gastrointestinal
GvHD ceased quickly and IS was reduced. Within routine
follow-up bone marrow aspirate on day 89 after allo-HSCT,
relapse of AML was diagnosed with an infiltration rate of 10%
myeloid blasts in cytomorphological work-up (Figures 1A,D),
which was confirmed by flow cytometry and chimerism analysis.
The genetic work-up now showed a loss of the previously
present FLT3-TKD mutation, which is known to happen in
about 7% of patients with relapsed AML (23). As salvage
therapy, the first cycle of azacytidine (75 mg/m2/d s.c. for
days 1–7 q4w) was begun and concurrently, as there were
no signs of GvHD, IS with prednisolone and cyclosporine
were reduced and discontinued by day 105 post allo-HSCT.
Despite discontinuation of IS, myeloid blasts in the peripheral
blood further increased and GvHD remained absent. Infection
during leucopenia was antibiotically treated with ciprofloxacin.
An effort to increase leucocyte count by filgastrim (GCSF-
support) was unsuccessful and due to thrombocytopenia, platelet
transfusions became necessary. Two weeks after initiation of
ciprofloxacin, the patient developed a maculopapular skin
rash, treated with topical ointments. Whether this was a
GvHD equivalent or an allergic reaction to ciprofloxacin
was unclear. Sustained pancytopenia seemed suspicious for
refractory disease, which was confirmed by bone marrow
aspirate with ∼50% blasts in cytomorphology and chimerism
of 45.5% (Figures 1B,E). Therefore, the therapeutic regimen
was altered to the biomodulatory treatment (APA) described
above although ATRA dosage soon had to be reduced due to
headaches. Within 3 weeks, the chimerism increased to 99.6%
(considered full chimerism) and AML blasts had completely
disappeared in the peripheral blood. The first APA cycle was
complicated by urosepsis with Staphylococcus epidermidis, which
was successfully treated with oral amoxicillin/clavulanic acid in
an outpatient setting. After complete remission of infectious signs
and symptoms and sustained absence of blasts in peripheral
blood, the second cycle of APA was administered. During
the second cycle, chronic GvHD (cGvHD) progressed with
additional ocular (grade 1) involvement, treated with topical
agents only. Response assessment via bone marrow aspirate
after the second cycle again demonstrated complete remission
in cytomorphology (Figures 1C,F) and flow cytometry. Because
FLT3 mutation was lost at relapse, there was no MRD marker
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FIGURE 1 | Cytomorphology of bone marrow aspirates (A–C depict an overview of the slide; D–F show the cells at greater magnification; objective 63x). (A,D) Show
a hypoplastic bone marrow after stem cell transplantation with up to 10% myeloblasts (marked by an arrow) resembling early relapse after allo-HSCT. Leukemic blasts
display a basophilic cytoplasm frequently containing vacuoles. (B,E) (after one cycle of AZA) demonstrate a hypercellular marrow with ∼50% of the previously
described leukemic blasts (progressive disease). (C,F) (after two cycles of APA) show a normocellular marrow with an increased and left-shifted erythropoiesis,
differentiated neutrophils and no evidence of an increased percentage of myeloblasts resembling complete remission.
for molecular genetic analysis. However, chimerisms were 99.3
and 100% in bone marrow and peripheral blood, respectively,
confirming complete remission. During the subsequent APA
cycles, cGvHD remained unchanged with mild skin, oral and
eye involvement. Treatment with APA was discontinued after 5
cycles due to sustained complete remission (validated by another
bone marrow aspirate analysis) and patient wish. Unfortunately,
almost 7 months after discontinuation of APA therapy, relapse
of AML was diagnosed. Pancytopenia, increment in lactate
dehydrogenase (LDH) and plummeting of chimerism had
developed within 3 weeks, suggesting fast kinetics. Subsequently,
a salvage therapy with azacytidine in combination with
venetoclax was administered but unfortunately failed to induce
a remission.
DISCUSSION AND CONCLUSION
The biomodulatory combination therapy with AZA, ATRA,
and PGZ rapidly lead to a complete remission in this high-
risk AML patient with very poor prognosis after having
had AML relapse within 3 months of allo-HSCT and failing
therapy with HMA. In line with previous data, a complete
response as well as cytomorphologic signs of differentiation
were observed after only two cycles of therapy taking into
account that the patient simultaneously developed cGvHD,
which has been associated with a graft-vs.-leukemia effect. In
this context, biomodulatory therapy might act synergistically
with graft-vs.-leukemia (GvL) effect since differentiation of blasts
may lead to (over)expression of antigens like proteinase 3
and other azurophil granule proteins which serve as targets
for both autologous and allogeneic T-cell responses (24, 25).
Induction of an interferon response as well as the up-
regulation of major histocompatibility class-I (MHC-I) genes by
DNA methyltransferase inhibition by azacytidine might further
enhance the T-cell response (26, 27). Therefore, therapy with
APA seems a promising option, especially for high-risk patients
with poor prognosis and few therapeutic alternatives, even
after allo-HSCT. To our knowledge this is the first report
to show efficacy of this biomodulatory therapy in the post
allo-HSCT setting. APA is currently being investigated within
a prospective, randomized, clinical trial (AMLSG26-16/AML-
ViVA, EudraCT number 2016-000421-39, ClinicalTrials.gov
Identifier: NCT02942758).
METHODS
All follow-up genetic analyses (molecular genetic testing
of FLT3-TKD low) have been performed within clinical
routine diagnostics at MLL (Munich Leukemia Laboratory,
Munich, Germany).
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